Monograph Details
|
|
Pain & Pyrexia
> Migraine and headache
|
|
CAFERGOT SUPPOSITORIES |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Ergot alkaloid. |
| Generic Name |
|
Ergotamine tartrate 2 mg, caffeine 100 mg; rectal supp. |
| Also |
|
• CAFERGOT
|
| Indications |
|
Migraine, migraine variants, cluster headaches. |
| Children |
|
Not recommended. |
| Adults |
|
1 supp rectally at onset of attack, then 1 supp after 1 hour if needed; max 2 supps/attack, 5 supps/week. |
| Contraindications |
|
Peripheral vascular disease. Coronary heart disease. Hypertension. Hepatic or renal dysfunction. Sepsis. Concomitant potent CYP3A4 inhibitors (eg, ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) or other vasoconstrictors. Labor & delivery. Pregnancy (Cat.X). |
| Precautions |
|
Monitor for ergotism; do not exceed recommended dose. Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Potentiated by CYP3A4 inhibitors (eg, protease inhibitors, macrolides, azole antifungals, saquinavir, nefazodone, fluoxetine, fluvoxamine, grapefruit juice, zileuton), propranolol, nicotine. Severe hypertension with sympathomimetics. |
| Adverse Reactions |
|
Vasoconstrictive complications or ergotism (eg, ischemia, cold extremities, vasospasm, ECG changes, hyper- or hypotension, numbness, gangrene, dizziness), precordial or muscle pain, tachycardia, bradycardia, nausea, vomiting, local edema, itching; rarely: retroperitoneal and pleuropulmonary fibrosis, cardiac valve fibrosis (chronic use). |
| How Supplied |
Tabs—100
Supps—12 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
